TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37161377
Drug: Single-dose MR-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose MR-guided partial breast irradiation (PBI)
Study: 37161571
Drug: Bedaquiline (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline (400-800 mg) and Rifampicin (150-600 mg)
Study: 37161571
Drug: Rifampicin (150-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (150-600 mg)
Study: 37161823
Drug: High-Intensity Lipid-Lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Lipid-Lowering Therapies
Study: 37162000
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application designed to support patients with insulin therapy
Study: 37162147
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of plecanatide
Study: 37162147
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of plecanatide
Study: 37162349
Drug: Model-based simulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-based simulations of various infusion modes
Study: 37162744
Drug: Tildrakizumab 200
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 200 mg every 4 weeks until week 24
Study: 37163360
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Radiotherapy (RT)
Study: 37163622
Drug: Epicutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicutaneous immunotherapy delivered by means of a peanut patch for 12 months
Study: 37163622
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered daily for 12 months
Study: 37163622
Drug: Epicutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicutaneous immunotherapy delivered by means of a peanut patch
Study: 37163623
Drug: Cabozantinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (40 mg daily) plus nivolumab (3 mg/kg) and ipilimumab (1 mg/kg)
Study: 37163623
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) and ipilimumab (1 mg/kg)
Study: 37164012
Drug: BNT162b4 (mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b4 (mRNA vaccine targeting conserved non-spike antigens)
Study: 37164012
Drug: BNT162b2 (spike-protein-encoding
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (spike-protein-encoding vaccine)
Study: 37164457
Drug: Monthly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly follow-up by a community-based stroke coordinator who identifies individual risk profiles and sets up action plans based on individual goals.
Study: 37164457
Drug: Monthly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly follow-up by a community-based stroke coordinator.
Study: 37164467
Drug: Low iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low iodine (20 µg/day) multivitamin and mineral supplement
Study: 37164467
Drug: Identical supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical supplement containing 200 µg/day
Study: 37164472
Drug: GBDPs group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBDPs group (treatment group)
Study: 37164838
Drug: Inclisiran 100
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 100 mg
Study: 37164838
Drug: Inclisiran 300
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 300 mg
Study: 37164957
Drug: Ansofaxine 80
Normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ansofaxine 80 mg/day
Study: 37164957
Drug: Ansofaxine 160
Normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ansofaxine 160 mg/day
Study: 37165711
Drug: Gradual weaning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual weaning of EVD treatment (multi-step increase of resistance over days)
Study: 37165711
Drug: Prompt closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt closure of EVD treatment
Study: 37165711
Drug: Gradual weaning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual weaning of EVD treatment
Study: 37165840
Drug: Zinpentraxin alfa
Normalized name: Zinpentraxin alfa
DrugBank: Zinpentraxin alfa (DB14852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinpentraxin alfa (RO7490677, PRM-151) administered intravenously weekly (QW) or every 4 weeks (Q4W)
Study: 37165930
Drug: TNX-102 SL
Normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX-102 SL 2.8 mg for 2 weeks, followed by 5.6 mg for 12 weeks
Study: 37166022
Drug: Short-term steroids
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term steroids
Study: 37166053
Drug: PEP503 (NBTXR3)
Normalized name: Hafnium oxide-containing nanoparticles nbtxr3
DrugBank: Hafnium oxide (DB17508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP503 (NBTXR3) nanoparticles with radiotherapy and concurrent chemotherapy
Study: 37166053
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (preoperative concurrent chemoradiotherapy)
Study: 37166151
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (600 mg of calcium plus 200 UI of cholecalciferol)
Study: 37166257
Drug: Dexamethasone 0.3
Normalized name: dexamethasone 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.3 mg/kg
Study: 37166385
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg at Week 0, Week 4, and every 12 weeks thereafter
Study: 37166484
Drug: Tislelizumab +
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab + DNA hypomethylating agent (HMA) + CAG regimen
Study: 37166675
Drug: MG Symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG Symptoms Patient-Reported Outcome (PRO)
Study: 37166675
Drug: Quantitative MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative MG (QMG)
Study: 37166675
Drug: MG Composite
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MG Composite (MGC)
Study: 37166675
Drug: MG-Activities of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG-Activities of Daily Living (MG-ADL)
Study: 37166675
Drug: MG Symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG Symptoms PRO
Study: 37166798
Drug: Diffusing alpha-emitter
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diffusing alpha-emitter radiation therapy (DaRT) with a physical dose of 10 Gy (equivalent weighted dose of 200 CGE) to the tumor.
Study: 37166817
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Therapy (ET) plus trastuzumab and pertuzumab
Study: 37166948
Drug: Memantine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine as an augmentative agent to a selective serotonin reuptake inhibitor
Study: 37166961
Drug: Daily dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dietary self-monitoring
Study: 37166961
Drug: Monthly dietary
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dietary self-monitoring
Study: 37166997
Drug: Small-molecule activator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-molecule activator of PP2A (SMAP, DT-061)
Study: 37167165
Drug: Ergoferon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergoferon (1 tablet, 2 times a day for 3 weeks)
Study: 37167764
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus relatlimab (NIVO + RELA; 480 mg and 160 mg, respectively)
Study: 37167764
Drug: Nivolumab (NIVO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (NIVO; 480 mg)
Study: 37168472
Drug: Rectal swabs
Normalized name: witch hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal swabs and molecular diagnostic tests for detection of enteropathogens
Study: 37169401
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for 24 months
Study: 37169499
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments for MG
Study: 37169499
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects from treatments
Study: 37169708
Drug: Emotion Focused
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion Focused Mindfulness Therapy (EFMT) group delivered by Zoom
Study: 37169780
Drug: Brain serotonin
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain serotonin 4 receptor binding
Study: 37170043
Drug: Subcutaneous opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous opioids
Study: 37170109
Drug: Mifepristone (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (1200 mg/day)
Study: 37170123
Drug: Open abdomen
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open abdomen (OA) management with negative peritoneal pressure therapy (NPPT) dressing
Study: 37170191
Drug: High-dose polyethylene
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose polyethylene glycol 3350 (PEG, 459 g) and Gatorade (1.5 times the standard-dose)
Study: 37170191
Drug: High-dose polyethylene
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose polyethylene glycol 3350 (PEG, 612 g) and Gatorade (2.0 times the standard-dose)
Study: 37170191
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of PEG (306 g to 357 g) and Gatorade
Study: 37170191
Drug: High-dose preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose preparations
Study: 37170307
Drug: Adjuvant intravesical
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intravesical instillations of the drug selected based on drug screens in patient derived organoids (PDO) - Epirubicin, Mitomycin C, Gemcitabine, or Docetaxel for 6 instillations once weekly.
Study: 37170709
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg IFS
Study: 37170709
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg OM
Study: 37170833
Drug: Lowest MEEi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest MEEi tertile (MEEi<0.031 mL/s/g)
Study: 37171081
Drug: Oral oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxytocin
Study: 37171620
Drug: Rituximab, bendamustine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab, bendamustine, and low-dose cytarabine (R-BAC)
Study: 37171721
Drug: Talazoparib (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (oral, 1 mg once daily)
Study: 37171851
Drug: Implementation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implementation intervention including real-time and web-based training, tobacco smoking treatment protocol, expert consultation, coaching, and organizational strategy meetings.
Study: 37172100
Drug: IMA101 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IMA101 treatment (T-cell infusion and low-dose IL2)
Study: 37172116
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (SBP target, 110 to <130 mmHg)
Study: 37172116
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SBP target, 130 to <150 mmHg)
Study: 37172200
Drug: Quadrivalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent meningococcal conjugate vaccine (one dose)
Study: 37172204
Drug: Venetoclax-based therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax-based therapies
Study: 37172204
Drug: Venetoclax-based treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax-based treatments
Study: 37172934
Drug: Necessity for
Normalized name: AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL TOPICAL LOTION [I KNOW Very Necessary Broad Spectrum SPF-40 Moisturizing Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necessity for analgesics
Study: 37172969
Drug: Neoadjuvant intratumoral
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neoadjuvant intratumoral influenza vaccine treatment
Study: 37173074
Drug: Chronic cough
Normalized name: Pediaclear Cough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic cough (CC)
Study: 37173074
Drug: CT parameters
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT parameters and CC
Study: 37173116
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg once daily for 7 days
Study: 37173224
Drug: Bispecific antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific antibodies and other emerging treatment strategies
Study: 37173291
Drug: Computerized vestibular
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized vestibular retraining therapy; 12 twice-weekly sessions.
Study: 37173365
Drug: OBI-3424 administered
Normalized name: phentermine hydrochloride Oral Capsule [Oby-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBI-3424 administered intravenously at doses of 1, 2, 4, 6, 8, or 12 mg/m
Study: 37173365
Drug: OBI-3424 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBI-3424 at 12 mg/m
Study: 37173512
Drug: Intranasal esketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intranasal esketamine treatment during induction phase (twice-weekly)
Study: 37173512
Drug: Intranasal esketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intranasal esketamine treatment during optimization/maintenance phase (individualized dosing)
Study: 37173512
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with esketamine (up to 4.5 years)
Study: 37173568
Drug: Active Shiatsu
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Shiatsu treatment
Study: 37173568
Drug: Sham Shiatsu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Shiatsu treatment
Study: 37173784
Drug: Citicoline 10
Normalized name: citicoline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 10 mg/kg/12h IV for 4 weeks plus supportive measures
Study: 37174643
Drug: Control (platform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (platform immunotherapy)
Study: 37174650
Drug: Probiotic formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic formula containing three bifidobacteria; details on dosage and duration not provided.
Study: 37175874
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg intravenously every 3 weeks × two doses)
Study: 37178647
Drug: Afatinib 18
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib 18 mg/m²/d
Study: 37178647
Drug: Afatinib 23
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib 23 mg/m²/d
Study: 37178932
Drug: Semi-weekly (BIW)
Normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-weekly (BIW) focal boosted prostate SBRT delivering 35 Gy in 5 fractions with an iso-toxic boost up to 50 Gy
Study: 37178932
Drug: Once-weekly (QW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly (QW) focal boosted prostate SBRT
Study: 37179415
Drug: 12-week home-based
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week home-based physical activity intervention aiming to increase daily steps by 2000 from baseline
Study: 37179458
Drug: Caregiver-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver-delivered cognitive stimulation therapy (CDCST) for 15 weeks
Study: 37179458
Drug: Caregiver-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver-delivered cognitive stimulation therapy (CDCST)
Study: 37179530
Drug: Multimodal mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal mechanical stimulation therapy (M-Stim) with three vibration motors (50 Hz, 100 Hz, 200 Hz) and amplitudes between 0.1-0.3 m/s for 20 minutes.
Study: 37180485
Drug: Macadamia nuts
Normalized name: Macadamia nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macadamia nuts (~15% of daily calories) for 8 weeks
Study: 37180505
Drug: Iptacopan 200
Normalized name: iptacopan 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iptacopan 200 mg twice daily for 24 months
Study: 37180745
Drug: Behavioral intersectional
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intersectional stigma coping intervention (three weekly 2-h group sessions)
Study: 37181036
Drug: Short-term rapid
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term rapid severe hypothyroidism induced by thyroid hormone withdrawal
Study: 37181130
Drug: Puerto Rican
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerto Rican Optimized Mediterranean-like Diet (PROMED) intervention group received 1 individual nutritional counseling session on a portion-control culturally-tailored MedDiet, daily text messages for 2 months, and supplied legumes and vegetable oils.
Study: 37181130
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received cooking utensils and one standard portion-control nutritional counseling session reinforced with daily texts for 2 months.
Study: 37181156
Drug: High fiber
Normalized name: High Fiber Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber (∼38 g/d) plant-based diet
Study: 37181420
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream as maintenance therapy after baseline therapy with topical glucocorticoids (group 1)
Study: 37181420
Drug: Topical glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticoids without subsequent use of pimecrolimus (group 2)
Study: 37181888
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral psilocybin (0.25 mg/kg)
Study: 37181888
Drug: Active placebo-control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo-control agent (250 mg of niacin)
Study: 37182434
Drug: MA (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA (160 mg orally daily)
Study: 37182434
Drug: MA +
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MA + LNG-IUS (MA 160 mg orally daily plus LNG-IUS)
Study: 37182534
Drug: Sulbactam-durlobactam (1·0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam-durlobactam (1·0 g of each drug in combination over 3 h every 6 h for 7-14 days)
Study: 37182534
Drug: Colistin (2·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin (2·5 mg/kg over 30 min every 12 h for 7-14 days)
Study: 37182695
Drug: Maternal UIC
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal UIC ≥250 μg/L
Study: 37182695
Drug: Maternal TSH
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal TSH ≥2.5 mIU/L
Study: 37183098
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine hydrochloride 1% i.v. at a dose of 1.5 mg/kg
Study: 37183103
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (≤2 years since chemotherapy completion)
Study: 37183520
Drug: Setanaxib 400
Normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setanaxib 400 mg OD
Study: 37183520
Drug: Setanaxib 400
Normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setanaxib 400 mg BID
Study: 37183528
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg plus chemotherapy (paclitaxel 200 mg/m2)
Study: 37183528
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (paclitaxel 200 mg/m2)
Study: 37183779
Drug: Brepocitinib 60
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brepocitinib 60 mg single oral dose
Study: 37183837
Drug: PEG-rhG-CSF (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF (100 μg/kg body weight, maximum total dosage of 6 mg) administered once 24-48 hours following chemotherapy for two cycles
Study: 37183871
Drug: 3-hydroxybutyrate (3-OHB)
Normalized name: 2-Amino-3-hydroxybutyric acid
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hydroxybutyrate (3-OHB) infusion